# Same-Day Magnetic Resonance-Guided Single-Fraction Stereotactic Body Radiation Therapy for Painful Non-Spine Bone Metastases – A Single-Center Study (“BONE SHOT”)

## TL;DR

A study tested a same-day treatment for bone metastases pain using MRI-guided radiation therapy and found it to be feasible and safe with some pain relief.

## Contribution

Demonstrates the feasibility and safety of same-day magnetic resonance-guided stereotactic body radiotherapy for non-spine bone metastases.

## Key findings

- All 13 patients completed the same-day workflow without major toxicity.
- Pain response rates were 73.3% overall and 20.0% complete at one week, improving to 66.7% and 53.3% at four weeks.
- Median on-table time for treatment was 65 minutes, indicating efficient workflow.

## Abstract

•High-dose single-fraction stereotactic body radiotherapy for painful non-spine bone metastases has shown to be efficacious.•This study (“BONE SHOT”) assessed feasibility of same-day magnetic resonance-guided planning and SBRT delivery.•All workflows were completed as planned; and treatments were well tolerated.•Overall and complete pain response rates were 73.3% and 20.0%, which evolved to 66.7% and 46.6% at four weeks after SBRT.•Same-day magnetic resonance-guided SBRT for non-spine bone metastases was feasible and safe.

High-dose single-fraction stereotactic body radiotherapy for painful non-spine bone metastases has shown to be efficacious.

This study (“BONE SHOT”) assessed feasibility of same-day magnetic resonance-guided planning and SBRT delivery.

All workflows were completed as planned; and treatments were well tolerated.

Overall and complete pain response rates were 73.3% and 20.0%, which evolved to 66.7% and 46.6% at four weeks after SBRT.

Same-day magnetic resonance-guided SBRT for non-spine bone metastases was feasible and safe.

There is evidence for efficacy of high-dose single-fraction stereotactic body radiotherapy (SF-SBRT) for painful non-spine bone metastases (NSBMs). This study (“BONE SHOT”) assessed feasibility of same-day magnetic resonance-guided (MRg) planning and SF-SBRT delivery, recorded toxicity and assessed efficacy for treating metastatic patients with NSBMs.

Patients with painful (≥3/10 points on a 0–10 numeric rating scale (NRS) for pain) and radiologically confirmed NSBMs from solid organ malignancies were eligible for this prospectively acquired, single-center study. Patients received MRg-SF-SBRT via MR-Linac (ViewRay®) with same-day consultation, consent, planning and treatment. Drop-out rate, procedure times, acute toxicity and pain response were recorded.

Between June 2019 and June 2020, 13 patients with 15 NSBMs were treated per protocol. Mean patient age was 64 (range, 30–87) years; most common primary cancer was gastrointestinal malignancies (38.5 %); most commonly treated site was pelvis (53.3 %). All workflows were completed as planned. Median on-table time for contouring, planning and delivery was 65 (range, 57–112) minutes. Treatments were well tolerated; one patient developed “pain flair”; no grade ≥ 3 toxicities were registered. At one week following SBRT, overall and complete pain response rates were 73.3 % and 20.0 %, respectively, which evolved to 66.7 % and 53.3 % at four weeks after SBRT; median pre-treatment pain score was 6 points, which was reduced by a median of 5 points (P = 0.0028) at four weeks.

The same-day MRg-SF-SBRT workflow for NSBMs was feasible, safe, and preliminary results indicate promising efficacy, warranting future trials investigating this intervention.